2015 American Society of Clinical Oncology Annual Meeting *

May 29-June 2, 2015; Chicago, Illinois
This program provides coverage of the 2015 ASCO annual meeting with downloadable slidesets and expert analysis of the most clinically relevant study results. Topics include solid tumors, hematologic malignancies, and immunotherapy.

Share

Program Content

Activities

Daratumumab in R/R MM
SIRIUS: Daratumumab Active, Safe in Double Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

MDS and <i>KIR</i> Genes
KIR Genes Associated With MDS Risk
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

Gilteritinib in R/R AML
FLT3/Axl Inhibitor Gilteritinib (ASP2215) Safe and Active in Relapsed or Refractory AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

Idelalisib + Ofatumumab in CLL
Improved PFS With Addition of Idelalisib to Ofatumumab in Previously Treated CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

CR30 as PFS Surrogate in FL
CR Rate at 30 Mos Is a Feasible Surrogate Endpoint for PFS in First-line Follicular Lymphoma Trials
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

BV+ R-CHOP in DLBCL
Frontline Brentuximab Vedotin + R-CHOP Yields High Response Rate in DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

Elo + Len/Dex in R/R MM
ELOQUENT-2: Addition of Elotuzumab to Len/Dex Extends PFS in Relapsed/Refractory Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

ENDEAVOR: Kd vs Vd in Relapsed MM
ENDEAVOR: Kd Superior to Vd in Relapsed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

KRd + ASCT in NDMM
Extended Carfilzomib, Lenalidomide, Dexamethasone + ASCT Effective in Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

Panobinostat/Carfilzomib in MM
Panobinostat/Carfilzomib With Promising Activity in R/R Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

CTL019 CAR T-cells in NHL
CD19 CAR-T Cells Induce Durable Responses in Relapsed/Refractory CD19-Positive Lymphomas
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

Outcomes w R-Chemo in FL
Poorer Outcomes With Rituximab + Chemo in Heavier Patients, Older Men With Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

HELIOS: Ibrutinib + BR in R/R CLL/SLL
HELIOS: Longer PFS With Addition of Ibrutinib to Bendamustine/Rituximab in Previously Treated CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

Pacritinib in Myelofibrosis
PERSIST-1: Pacritinib Improved Spleen Volume Reductions in Myelofibrosis vs Best Available Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

GADOLIN Trial in iNHL
GADOLIN: Obinutuzumab + Bendamustine and Maintenance Obinutuzumab in Rituximab-Refractory Indolent NHL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

LSC Phenotypes and Outcomes
Leukemia Stem Cell Phenotypes Correlate With Cytogenetic Risk Factors and Clinical Outcomes
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

Downloadable Slideset
Key Studies in Hematologic Malignancies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 25, 2015

Expires: August 23, 2016

19-28ζ CAR T-cells in R/R ALL
19-28ζ CAR T-Cells Induce High CR Rate in Relapsed/Refractory Adult ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Activities

MMR Deficiency
Tumors Deficient in Mismatch Repair Particularly Susceptible to Immune Checkpoint Blockade
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2015

Expires: May 29, 2016

Vitamin D Levels in mCRC
Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2015

Expires: May 30, 2016

INTEGRATE: Regorafenib in GE Cancer
INTEGRATE: Regorafenib Prolonged PFS in Previously Treated GE Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2015

Expires: May 30, 2016

Aspirin Secondary Prevention
Aspirin Associated With Reduced Mortality in Patients With CRC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2015

Expires: May 30, 2016

SIRT in First-line mCRC
SIRFLOX: Addition of SIRT to mFOLFOX6 ± Bevacizumab in First-line mCRC Improves Liver Disease Control
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2015

Expires: May 30, 2016

Pembrolizumab in Gastric Cancer
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2015

Expires: May 31, 2016

mFOLFIRINOX/Radiation in PDAC
Alliance A021101: Preoperative mFOLFIRINOX + Chemoradiation in Borderline Resectable Pancreatic Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2015

Expires: June 01, 2016

CME Slideset
Gastrointestinal Cancers
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 31, 2015

Expires: July 30, 2016

Activities

Sunitinib, Everolimus in NCRCC
ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2015

Expires: June 02, 2016

mTOR Mutations in RCC
Mutations Predict Responses to mTOR Inhibitors in mRCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2015

Expires: June 02, 2016

Biomarkers for Nivolumab in mRCC
Predictive Biomarkers and Nivolumab Activity in mRCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2015

Expires: June 02, 2016

Apatorsen in Bladder Ca
Borealis-1: Apatorsen + Gemcitabine/Cisplatin for Pts With Advanced Bladder Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2015

Expires: June 02, 2016

Eribulin in Urothelial Cancer
NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2015

Expires: June 02, 2016

Maintenance Lapatinib in UBC
Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2015

Expires: June 02, 2016

ASSURE: Dose Analysis
ASSURE: Dose Reduction of Sunitinib or Sorafenib Not Associated With Improved Outcomes in Resected RCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2015

Expires: June 02, 2016

Atezolizumab in UBC
Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

KEYNOTE-012: Pembrolizumab
KEYNOTE-012: Pembrolizumab Shows Promising Antitumor Activity and Safety in Advanced Urothelial Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

Docetaxel in Prostate Cancer
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

mCRPC: Histologic Subtypes
Intermediate Atypical Carcinoma: Novel Histological Subtype of mCRPC in Patients Resistant to Androgen Receptor Agonists
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

SYNERGY Reanalysis
SYNERGY: Custirsen in Poor-Prognosis mCRPC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

Downloadable Slideset
Genitourinary Cancers
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 20, 2015

Expires: August 18, 2016

Lenvatinib ± Everolimus in mRCC
Improved Survival and Response With Lenvatinib ± Everolimus vs Everolimus Alone in Metastatic RCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Activities

CheckMate 057
CheckMate 057: Nivolumab Superior to Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2015

Expires: May 29, 2016

Pembrolizumab in SCLC
KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1-Positive Extensive-Stage SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2015

Expires: May 30, 2016

First-Line AZD9291 in EGFR- Mutant NSCLC
AURA: AZD9291 Active and Safe in Untreated EGFR Mutation–Positive Advanced NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2015

Expires: May 30, 2016

CheckMate 017
CheckMate 017: Nivolumab Superior to Docetaxel in Previously Treated Advanced Squamous NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2015

Expires: May 30, 2016

KEYNOTE-021 NSCLC
KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2015

Expires: May 31, 2016

MAPS: Bevacizumab in MPM
MAPS: Adding Bevacizumab to Pemetrexed/Cisplatin Increases Survival in Patients With Malignant Pleural Mesothelioma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2015

Expires: May 31, 2016

Rociletinib in EGFR Mutant NSCLC
TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2015

Expires: May 31, 2016

POPLAR: Atezolizumab in NSCLC
POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2015

Expires: May 31, 2016

Dabrafenib/trametinib in BRAF+ NSCLC
Dabrafenib + Trametinib Demonstrated Promising Activity in Pretreated BRAF V600E–Positive Advanced NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2015

Expires: June 01, 2016

Downloadable Slideset
Lung Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 07, 2015

Expires: August 05, 2016

Nivolumab ± Ipilimumab in SCLC
CheckMate 032: Nivolumab ± Ipilimumab With Promising Activity in Recurrent SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Activities

CheckMate 057
CheckMate 057: Nivolumab Superior to Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2015

Expires: May 29, 2016

MMR Deficiency
Tumors Deficient in Mismatch Repair Particularly Susceptible to Immune Checkpoint Blockade
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2015

Expires: May 29, 2016

CA209-040 Nivolumab in HCC
CA209-040: Nivolumab With Promising Safety and Antitumor Activity in Advanced HCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2015

Expires: May 29, 2016

Pembrolizumab in SCLC
KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1-Positive Extensive-Stage SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2015

Expires: May 30, 2016

CheckMate 017
CheckMate 017: Nivolumab Superior to Docetaxel in Previously Treated Advanced Squamous NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2015

Expires: May 30, 2016

CheckMate 067
CheckMate 067: Nivolumab + Ipilimumab and Nivolumab Alone Superior to Ipilimumab Alone in Previously Untreated Advanced Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2015

Expires: May 31, 2016

Immunogenic Antigens
Molecular Insight Into Lack of Response of Some Melanomas to Immunotherapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2015

Expires: June 01, 2016

PD-L1/MEK/BRAF in Melanoma
Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2015

Expires: June 01, 2016

Biomarkers for Nivolumab in mRCC
Predictive Biomarkers and Nivolumab Activity in mRCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2015

Expires: June 02, 2016

Atezolizumab in UBC
Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

KEYNOTE-012: Pembrolizumab
KEYNOTE-012: Pembrolizumab Shows Promising Antitumor Activity and Safety in Advanced Urothelial Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2015

Expires: June 03, 2016

Downloadable Slideset
Cancer Immunotherapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 25, 2015

Expires: August 23, 2016

Nivolumab ± Ipilimumab in SCLC
CheckMate 032: Nivolumab ± Ipilimumab With Promising Activity in Recurrent SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

Thomas H. Cartwright, MD

US Oncology GI Research

Associate Professor of Medicine

University of Central Florida School of Medicine

Orlando, Florida

Provided by

ProCE Banner

Supporters

This activity is supported by independent educational grants from

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.